Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
A total of 24 patients are currently receiving or have completed treatment with MAT2203 under the Compassionate/Expanded Use Access Program, and four additional cases are awaiting submission and/or FDA approval. In each instance, the patient was not responding to azole therapy, was unable to receive azole therapy due to drug/drug interactions or was unable to tolerate IV-amphotericin B for an appropriate treatment duration due to toxicity. In all patients who experienced serious renal toxicity while receiving IV-amphotericin B who were subsequently treated with MAT2203, renal toxicity was reversed, and renal function returned to baseline. MAT2203 is not yet licensed or approved anywhere globally.